Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 80 years old
- People who have been diagnosed with a specific type of brain tumour called diffuse glioma (a higher-grade type, classified as WHO Grade 3 or 4), confirmed by laboratory testing of tumour tissue
- People who have already completed standard treatment, which may have included surgery (either a biopsy or tumour removal), radiotherapy, and/or chemotherapy
- People whose tumour has shown signs of growing or returning, as measured by a specific brain scan (MRI) method called RANO 2.0 (confirm with trial site for exact details)
- People whose tumour is in one single location in the brain (not spread to multiple areas)
- For people who had tumour removal surgery: the remaining tumour must be smaller than 50 ml in volume and less than 1 cm thick on a specific type of MRI scan
- For people who had a biopsy only: the tumour must be no more than 2 cm across at its widest point
- People who are generally able to carry out most daily activities, as measured by a standard medical scoring system called the Karnofsky Performance Scale (score above 70)
- People who are able to give their informed consent to take part in the study
Who may not be able to join:
- People who need urgent brain surgery, for example due to a sudden dangerous rise in pressure inside the skull
- People who have had serious complications after recent surgery, such as a low activity score on the Karnofsky scale (below 70), a wound infection, or a leak of fluid surrounding the brain and spinal cord
- People who have a brain fluid drainage device (ventricular shunt) that is leaking more than 10% during a standard check
- People whose surgical cavity (the space left after tumour removal) is open or connected to surrounding spaces in a way that could cause problems (confirm with trial site)
- People whose brain scan shows a significant shift of brain structures to one side (more than 5 mm), or who are experiencing symptoms such as nausea, vomiting, reduced consciousness, or significant swelling behind the eyes
- People with a blocked catheter (a tube used to deliver treatment)
- People whose life expectancy is estimated to be less than 3 months
- People who are unable to communicate or cooperate with the medical team
- People who are unable to give free and informed consent to participate
- People who are currently taking part in another medical research study
- People who have taken another experimental drug within 1 month before the start of this trial
- People who have previously been treated with the specific experimental substance used in this trial, called [²²⁵Ac]Ac-DOTA-SP
- People who are pregnant or breastfeeding
- People with serious conditions affecting other organs that, in the opinion of the treating doctor, would significantly increase the risks of the procedure
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Przemysław Kunert, Professor, Department of Neurosurgery, Medical University of Warsaw, Poland
Phone: +48 22 599 2575
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients experiencing clinical progression (as defined below)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.